<DOC>
	<DOCNO>NCT01252056</DOCNO>
	<brief_summary>The efficacy safety Cilostazol Probucol combination patient diabetic nephropathy good single use .</brief_summary>
	<brief_title>A Clinical Study Evaluate Efficacy Safety Cilostazol Probucol Combination Patients With Diabetic Nephropathy</brief_title>
	<detailed_description>The objective study : 1 . To evaluate efficacy Probucol defer nephropathy development patient diabetic nephropathy ( include : change value urine albumin baseline , rate patient serum creatinine reach double base-line serum creatinine , rate hemodialysis-free survival ) . 2 . To evaluate efficacy Cliostazol Probucol combination defer nephropathy development patient diabetic nephropathy 3 . To evaluate efficacy Cilostazol Probucol combination atherosclerosis related biomarkers change . Atherosclerosis related biomarkers include : ( ) Endothelium parameter : ICAM-1 , vWF , VCAM-1 , McP-1 . ( b ) Finolysis parameter : TM . ( c ) Inflammation parameter : Hs-CRP ; IL-6 . ( ) Oxidation parameter : Ox-LDL , 8-OHdG . ( e ) Lipid parameter : TC , LDL-C , HDL-C , TG . 4 . To evaluate efficacy Cilostazol Probucol combination progress carotid intima-media thickness ( IMT ) patient diabetic nephropathy . 5 . To evaluate safety Cilostazol Probucol combination patient diabetic nephropathy .</detailed_description>
	<mesh_term>Kidney Diseases</mesh_term>
	<mesh_term>Diabetic Nephropathies</mesh_term>
	<mesh_term>Cilostazol</mesh_term>
	<mesh_term>Probucol</mesh_term>
	<criteria>Male female age 40~75 year old Type 2 diabetes mellitus 6 month HbA1c ≤8 % Twice ( 2week interval ) confirm urinary albumin 303000µg/mg.cre Receive routine dosage ACEI ARB treatment 2 month , dosage fix least 1 month LDLC &gt; 100 mg/dL ( 2.60 mmol/L ) and/ hyperlipidemia patient Statins treatment Free sign inform consent form Has allergic history investigational drug Receive antilipemic agent ( except Statins ) within late 2 month , include Probucol Receive antiplatelet anticoagulation agent ( except Aspirin ) within late 2 month , include Cilostazol Rapid progression nephropathy within late 3 month Kidney disease cause reason accord medical history Serum potassium level le 3.5 mEq/L 5.5 mEq/L Hemorrhagic tendency hemorrhagic disease ( alimentary tract hemorrhage , active fundus hemorrhage , etc . ) Has myocardial infarction , angina pectoris , cerebral infarction within late 3 month Congestive heart failure Pregnant , potentially pregnant , lactate woman Severe hepatic inadequacy ( AST ALT 2.5 time high upper limit normal value range ) Serum creatinine level 1.5 time high upper limit normal value range Persistent hardly control hypertension ( malignant hypertension , SBP≥170 mmHg and/ DBP≥100 mmHg ) Severe ventricular arrhythmia ( multiple multifocal premature ventricular contraction ) Has medical history cardiac syncope primary syncope Has condition may prolong QT interval ( congenital long QT syndrome , take drug prolong QT interval , hypokalemia hypomagnesemia , etc . ) , man QT interval＞450msec , woman QT interval＞470msec Has severe complication ( diabetes mellitus ketoacidosis , nonketotic hyperosmolar diabetic coma , malignant tumor , severe anaemia , severe hematologic disease , etc . ) Register clinical trial within late 3 month Other condition would exclude study accord doctors'judgment</criteria>
	<gender>All</gender>
	<minimum_age>40 Years</minimum_age>
	<maximum_age>75 Years</maximum_age>
	<verification_date>May 2013</verification_date>
</DOC>